Literature DB >> 29276285

Formulary Drug Review: Safinamide.

Danial E Baker1, Anne P Kim2.   

Abstract

Entities:  

Year:  2017        PMID： 29276285      PMCID： PMC5735722          DOI： 10.1177/0018578717726046

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


× No keyword cloud information.
  22 in total

1.  Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound.

Authors:  P Salvati; R Maj; C Caccia; M A Cervini; M G Fornaretto; E Lamberti; P Pevarello; G A Skeen; H S White; H H Wolf; L Faravelli; M Mazzanti; E Mancinelli; M Varasi; R G Fariello
Journal:  J Pharmacol Exp Ther       Date:  1999-03       Impact factor: 4.030

2.  Preclinical evaluation of PNU-151774E as a novel anticonvulsant.

Authors:  R G Fariello; R A McArthur; A Bonsignori; M A Cervini; R Maj; P Marrari; P Pevarello; H H Wolf; J W Woodhead; H S White; M Varasi; P Salvati; C Post
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

3.  Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects.

Authors:  Sonja Krösser; Anne Marquet; Dieter Gallemann; Peter Wolna; Nicolas Fauchoux; Robert Hermann; Andreas Johne
Journal:  Biopharm Drug Dispos       Date:  2012-11-19       Impact factor: 1.627

4.  PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat.

Authors:  R Maj; R G Fariello; G Ukmar; M Varasi; P Pevarello; R A McArthur; P Salvati
Journal:  Eur J Pharmacol       Date:  1998-10-16       Impact factor: 4.432

5.  Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease.

Authors:  A H V Schapira; F Stocchi; R Borgohain; M Onofrj; M Bhatt; P Lorenzana; V Lucini; R Giuliani; R Anand
Journal:  Eur J Neurol       Date:  2012-09-12       Impact factor: 6.089

6.  Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition.

Authors:  Carlo Cattaneo; Carla Caccia; Antonio Marzo; Roberto Maj; Ruggero G Fariello
Journal:  Clin Neuropharmacol       Date:  2003 Jul-Aug       Impact factor: 1.592

7.  Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers.

Authors:  Chiara Leuratti; Marco Sardina; Paolo Ventura; Alessandro Assandri; Markus Müller; Martin Brunner
Journal:  Pharmacology       Date:  2013-10-11       Impact factor: 2.547

8.  Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis.

Authors:  Carlo Cattaneo; Paolo Barone; Erminio Bonizzoni; Marco Sardina
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

9.  Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.

Authors:  Carlo Cattaneo; R La Ferla; Erminio Bonizzoni; Marco Sardina
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

10.  Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.

Authors:  Carlo Cattaneo; Marco Sardina; Ermino Bonizzoni
Journal:  J Parkinsons Dis       Date:  2016       Impact factor: 5.568
View more
  1 in total

1.  Real life evaluation of safinamide effectiveness in Parkinson's disease.

Authors:  Francesca Mancini; Alessio Di Fonzo; Giulia Lazzeri; Linda Borellini; Vincenzo Silani; Marco Lacerenza; Cristoforo Comi
Journal:  Neurol Sci       Date:  2018-02-13       Impact factor: 3.307
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.